Ashford and St Peter's Hospitals NHS Foundation Trust, Ashford, UK.
BMC Ophthalmol. 2021 Oct 25;21(1):379. doi: 10.1186/s12886-021-02142-8.
This study was designed to evaluate visual, refractive and safety outcomes in eyes after they underwent phacoemulsification and implantation of a preloaded monofocal hydrophobic acrylic intraocular lens.
This was a single center observational study conducted at Ashford and St Peter's Hospitals NHS Foundation Trust, United Kingdom. Patients were included if they had cataract extraction with in-the-bag implantation of the EyeCee® One preloaded intraocular lens from August to October 2019. Pre-operative, surgery-related and 2 weeks and 3 months post-operative data was collected. Surgeons at this trust were then asked to complete a feedback form to evaluate their experience of implanting the EyeCee® One.
One hundred fifty-two eyes were included in the study. Ninety-four (62%) of these eyes had cataract but no concomitant ocular pathology that could potentially affect visual acuity. Three months post-operatively, 98.7% of all eyes had monocular CDVA ≤0.3 logMAR. 100% of the eyes without concomitant ocular pathology achieved this target. The mean CDVA of all eyes in this study improved from 0.43 ± 0.43 logMAR pre-operatively, to 0.05 ± 0.11 logMAR post-operatively (p < 0.05). The mean sphere and spherical equivalent values showed significant improvements (p < 0.05) and (p < 0.05). There were no intraoperative complications and 1.3% of patients reported complications 2 weeks post-operatively. All of the participating surgeons said they would use the EyeCee® One again with 64% providing an overall rating of 'excellent' for their experience of implanting this intraocular lens.
This study indicates excellent post-operative visual acuity and refractive outcomes in eyes after EyeCee® One implantation. This is accompanied with very little risk of intraoperative and post-operative complications.
本研究旨在评估行白内障超声乳化吸除术联合预装单焦疏水性丙烯酸人工晶状体植入术后患者的视力、屈光度和安全性。
这是一项在英国阿什福德和圣彼得医院 NHS 基金会信托基金进行的单中心观察性研究。如果患者在 2019 年 8 月至 10 月期间行白内障超声乳化吸除术联合预装 EyeCee® One 人工晶状体囊袋内植入术,即被纳入研究。收集患者术前、手术相关以及术后 2 周和 3 个月的数据。本中心的外科医生随后被要求填写一份反馈表,以评估他们植入 EyeCee® One 的经验。
本研究共纳入 152 只眼。其中 94 只(62%)眼患有白内障,但无可能影响视力的其他眼部疾病。术后 3 个月,所有眼的单眼最佳矫正视力(BCVA)均≤0.3 对数视力记录(logMAR)。无其他眼部疾病的眼 100%达到此目标。本研究中所有眼的平均 BCVA 从术前的 0.43±0.43 logMAR 提高到术后的 0.05±0.11 logMAR(p<0.05)。平均球镜和等效球镜值均显著改善(p<0.05)和(p<0.05)。术中无并发症,1.3%的患者术后 2 周报告并发症。所有参与的外科医生均表示将再次使用 EyeCee® One,64%的外科医生对植入该人工晶状体的体验给予“优秀”的总体评价。
本研究表明 EyeCee® One 植入术后患者的术后视力和屈光结果良好,且术中及术后并发症风险极低。